SCAI: Ixmyelocel-T studied for dilated cardiomyopathy

May 15, 2012
SCAI: ixmyelocel-T studied for dilated cardiomyopathy

(HealthDay) -- For patients with dilated cardiomyopathy, treatment with an autologous bone marrow-derived, expanded multi-cell product, ixmyelocel-T, is well tolerated and associated with improved symptoms at one year, according to a study presented at the Society for Cardiovascular Angiography and Interventions 2012 Scientific Sessions, held from May 9 to 12 in Las Vegas.

Timothy Henry, M.D., from the Minneapolis Heart Institute Foundation at Abbot Northwestern Hospital in Minnesota, and colleagues conducted a phase 2a trial to assess the safety and preliminary efficacy of intramyocardial delivery of ixmyelocel-T in 22 patients with ischemic and non-ischemic dilated cardiomyopathy. Participants with New York Heart Association (NYHA) Class III/IV, a of 30 percent, and limited treatment options were randomly allocated in a 2:1 ratio to ixmyelocel-T or control. were cultured to expand the number of activated macrophages and and then injected into the after cardiac mapping. Safety and efficacy were assessed at baseline and at three, six, and 12 months.

The researchers found that there were no procedural complications and no between-group differences in adverse events. Improved clinical outcomes were seen in patients with ischemic dilated cardiomyopathy, with a mean number of 0.22 major adverse cardiovascular events, versus 1.67 in control patients. Compared with controls or patients with non-ischemic dilated cardiomyopathy, more patients with ischemic dilated cardiomyopathy had improvements in NYHA Class, six-minute walk distance, and ejection fraction.

"Treatment with ixmyelocel-T was well tolerated and patients who received the cell therapy showed improved symptoms after one year," Henry said in a statement. "The results provide a strong basis for a larger clinical trial of this treatment in patients with dilated cardiomyopathy."

Several authors disclosed financial ties to biotechnology companies, including Aastrom Biosciences, which funded the study.

Explore further: Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure

More information: Press Release
More Information

Related Stories

Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure

March 27, 2012
(Medical Xpress) -- Researchers have identified genetic causes in nearly 1 in 5 patients who suffer a type of heart failure called dilated cardiomyopathy.

Study finds important risk factors for death/transplantation in children with heart muscle disease

July 25, 2011
Researchers have identified important risk factors for death and transplantation in children with dilated cardiomyopathy (heart muscle disease), according to results from a study supported by the National Heart, Lung, and ...

Cell therapy using patient's own bone marrow may present option for heart disease

March 24, 2012
Cell therapy may present an option for patients with ischemic heart disease to use their own bone marrow cells to repair the damaged areas of their hearts, and may pave the way for future treatment options, according to the ...

Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy

November 14, 2011
Cardiomyopathy is common among cardiac arrest survivors. The survival and neuroprotective benefits of therapeutic hypothermia is similar in patients with preexisting cardiomyopathy, compared with those patients without cardiomyopathy, ...

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.